Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecast
ARQT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $38.38 average of analyst targets
- Upside to target
- +33.2% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $0.17
- 52-week range
- $19.50 – $31.20
ARQT analyst ratings
8 analystsNumber of analysts at each rating.
ARQT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ARQT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.17 | $0.14 | $0.20 | $0.06 | +191.7% | 6 |
| Current fiscal year (2026) | $0.43 | $0.20 | $0.62 | −$0.13 | +432.1% | 6 |
| Next fiscal year (2027) | $1.27 | $0.80 | $1.72 | $0.43 | +193.4% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ARQT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $142.6M | $140.3M | $146.5M | +43.7% | 7 |
| Current fiscal year (2026) | $537.8M | $529.3M | $548.7M | +43.0% | 8 |
| Next fiscal year (2027) | $686.8M | $653.4M | $709.9M | +27.7% | 8 |
ARQT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ARQT revenue: reported and forecast
ARQT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.08 | $0.16 | $0.16 | $0.17 | $0.17 | +123.5% | 3 up · 0 down |
| Current fiscal year (2026) | $0.18 | $0.41 | $0.41 | $0.43 | $0.43 | +144.3% | 4 up · 0 down |
| Next fiscal year (2027) | $1.13 | $1.30 | $1.30 | $1.36 | $1.27 | +11.8% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ARQT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ARQT beat in 11 of 12.
What analysts expect from ARQT
8 analysts cover Arcutis Biotherapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $38.38, 33.2% above the latest close of $28.82. Analysts expect earnings of $0.43 per share for 2026, +432.1% from a year earlier. For 2027 the average estimate is $1.27 per share on revenue of $686.8 million. Arcutis Biotherapeutics beat the EPS estimate in 11 of the last 12 quarters.
Related: ARQT income statement, ARQT key metrics, ARQT chart. See the ARQT stock overview for the latest quote and news.
ARQT forecast FAQ
What is Arcutis Biotherapeutics's price target?
The average analyst price target for Arcutis Biotherapeutics is $38.38, 33.2% above the latest close of $28.82.
Is Arcutis Biotherapeutics a buy, hold or sell?
Of 8 analysts covering Arcutis Biotherapeutics, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Arcutis Biotherapeutics's EPS forecast?
Analysts forecast $0.43 per share for 2026 (range $0.20 to $0.62); for 2027 the estimate is $1.27.
What is Arcutis Biotherapeutics's revenue forecast?
The average revenue estimate for 2026 is $537.8 million, growth of 43.0%; for 2027 it is $686.8 million.
When does Arcutis Biotherapeutics report earnings?
Arcutis Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes; the EPS estimate is $0.17.
Does Arcutis Biotherapeutics usually beat earnings estimates?
Arcutis Biotherapeutics reported EPS at or above the analyst estimate in 11 of the last 12 quarters.